Cadence Capital Management LLC decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 100,503 shares of the company’s stock after selling 4,156 shares during the period. Johnson & Johnson makes up approximately 0.9% of Cadence Capital Management LLC’s investment portfolio, making the stock its 12th biggest position. Cadence Capital Management LLC’s holdings in Johnson & Johnson were worth $14,042,000 at the end of the most recent reporting period.
Other institutional investors have also recently modified their holdings of the company. Goodman Financial Corp purchased a new position in shares of Johnson & Johnson during the fourth quarter valued at about $104,000. Price Wealth Management Inc. purchased a new position in shares of Johnson & Johnson during the fourth quarter valued at about $148,000. Roble Belko & Company Inc grew its position in shares of Johnson & Johnson by 59.7% during the fourth quarter. Roble Belko & Company Inc now owns 1,164 shares of the company’s stock valued at $163,000 after purchasing an additional 435 shares in the last quarter. Cerebellum GP LLC purchased a new position in shares of Johnson & Johnson during the fourth quarter valued at about $166,000. Finally, Jentner Corp purchased a new position in shares of Johnson & Johnson during the fourth quarter valued at about $209,000. Hedge funds and other institutional investors own 66.16% of the company’s stock.
Shares of Johnson & Johnson opened at $123.72 on Tuesday, according to Marketbeat. The company has a quick ratio of 1.25, a current ratio of 1.58 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $333.32 billion, a price-to-earnings ratio of 16.95, a PEG ratio of 1.90 and a beta of 0.74. Johnson & Johnson has a 1 year low of $121.28 and a 1 year high of $148.32.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, April 17th. The company reported $2.06 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.00 by $0.06. The business had revenue of $20.01 billion during the quarter, compared to the consensus estimate of $19.50 billion. Johnson & Johnson had a net margin of 1.58% and a return on equity of 30.65%. The firm’s quarterly revenue was up 12.6% compared to the same quarter last year. During the same quarter last year, the firm earned $1.83 earnings per share. sell-side analysts predict that Johnson & Johnson will post 8.13 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 12th. Shareholders of record on Tuesday, May 29th will be paid a $0.90 dividend. The ex-dividend date of this dividend is Friday, May 25th. This represents a $3.60 annualized dividend and a yield of 2.91%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.84. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.03%.
JNJ has been the subject of a number of research analyst reports. Zacks Investment Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $146.00 price objective for the company in a research report on Thursday, April 5th. Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $152.28 price objective for the company in a research report on Tuesday, January 23rd. Stifel Nicolaus raised their price objective on Johnson & Johnson from $142.00 to $145.00 and gave the company a “hold” rating in a research report on Wednesday, January 24th. Credit Suisse Group set a $154.00 price objective on Johnson & Johnson and gave the company a “hold” rating in a research report on Monday, January 22nd. Finally, ValuEngine downgraded shares of Johnson & Johnson from a “hold” rating to a “sell” rating in a report on Tuesday. Six analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $142.23.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.